Assessment of the ethical consequences of genotype-based pharmacotherapy;Ethische folgeneinschätzung von genotyp-basierten arzneimitteltherapien

Deutsche Medizinische Wochenschrift

Volumn 127, Issue 47, 2002, Pages 2524-2526

  Meyer, Thomas ^a   Vinkemeier, U ^a,b   Meyer, U ^c  

^a LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ETHICS; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN GENOME; MEDICAL ETHICS; PHARMACOGENETICS; RECOMBINANT DNA TECHNOLOGY; REVIEW;

DRUG THERAPY; GENOTYPE; HUMANS; PATIENT RIGHTS; PHARMACOGENETICS; PHYSICIAN-PATIENT RELATIONS;

EID: 0037159844     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-35638     Document Type: Review

References (17)

1. Anderlik MR, Rothstein MA. Privacy and confidentiality of genetic information: What rules for the new science? Annu Rev Genomics Hum Genet 2001; 2: 401-433
2. Evans WE, Johnson JA. Pharmacogenomics: The inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001; 2: 9-39
3. Galjaard H. New names for old disciplines. J Inherit Metab Dis 2002; 25: 139-156
4. Ginsburg GS, McCarthy JJ. Personalized medicine: Revolutionizing drug discovery and patient care. Trends Biotechnol 2001; 19: 491-496
5. Issa AM. Ethical considerations in clinical pharmacogenomics research. Trends Pharmacol Sci 2000; 21: 247-249
6. Issa AM, Keyserlingk EW. Apolipoprotein E genotyping for pharmacogenetic purposes in Alzheimer's disease: Emerging ethical issues. Can J Psychiatry 2000; 45: 917-922
7. Jones JK. Pharmacogenetics and pharmacoepidemiology. Pharmacoepidemiol Drug Saf 2001; 10: 457-461
8. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, Lie KI, Kastelein JJ. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998; 338: 86-93
9. Mancinelli L, Cronin M, Sadee W. Pharmacogenomics: The promise of personalized medicine. AAPS PharmSci 2000; 2: E4, 1-12
10. March R, Cheeseman K, Doherty M. Pharmacogenetics - Legal, ethical and regulatory considerations. Pharmacogenomics 2001; 2: 317-327
11. Meyer T, Vinkemeier U, Meyer U. Medizinethische implikationen zukünftiger pharmakogenomischer behandlungsstrategien. Ethik Med 2002; 14: 3-10
12. Møldrup C. Ethical, social and legal implications of pharmacogenomics: A critical review. Community Genet 2001; 4: 204-214
13. Nebert DW, Bingham E. Pharmacogenomics: Out of the lab and into the community. Trends Biotechnol 2001; 19: 519-523
14. Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, Hui S, Bertrand P, Nalbantoglu J, Gilfix BM, Gauthier S. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A 1995; 92: 12260-12264
15. Rothstein MA, Epps PG. Ethical and legal implications of pharmacogenomics. Nat Rev Genet 2001; 2: 228-231
16. Rusnak JM, Kisabeth RM, Herbert DP, McNeil DM. Pharmacogenomics: A clinician's primer on emerging technologies for improved patient care. Mayo Clin Proc 2001; 76: 299-309
17. Thomas SM. Pharmacogenetics: The ethical context. Pharmacogenomics J 2001; 1: 239-242